San Antonio Breast Cancer Symposium

San Antonio Breast Cancer Symposium

July 14, 2019
1 min read
Save

Breast cancer researcher to receive memorial lecture award

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Joseph A. Sparano, MD
Joseph A. Sparano

Joseph A. Sparano, MD, associate director for clinical research at Montefiore Einstein Center for Cancer Care at Albert Einstein Cancer Center, will receive the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium.

The topic of Sparano’s award lecture will be announced closer to the symposium, which will be held Dec. 10-14.

The award recognizes Sparano for his leadership, collaboration and practice-changing achievements in translational and clinical breast cancer research.

Sparano, vice chair of ECOG-ACRIN Cancer Research Group, has helped design and implement several pivotal trials designed to identify biomarkers to predict breast cancer recurrence, as well as evaluate the ideal chemotherapy regimen to prevent cancer recurrence after surgery. He served as study chair for the TAILORx trial, which showed use of a gene expression profile test could help predict which women with early-stage breast cancer can forgo chemotherapy.

“Through his high-impact work, Dr. Sparano has contributed toward important progress in the care of patients with breast cancer,” Carlos L. Arteaga, MD, director of Harold C. Simmons Comprehensive Cancer Center at UT Southwestern and co-director of San Antonio Breast Cancer Symposium, said in a press release. “Thanks to his leadership, we have a better understanding of breast cancer’s risk of recurrence, and crucial information about which patients will do best on which treatments. His research has helped clinicians personalize care for their patients, avoiding overtreatment for those at low risk for recurrence and improving clinical monitoring for those at high risk.”